StemGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
For the nine months, sales was USD 0.02 million compared to USD 0.039 million a year ago. Net loss was USD 0.40319 million compared to USD 0.299751 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.